ResMed Inc. entered into an accelerated share repurchase agreement with Citibank to buy back $450 million of its common stock on August 31, 2026. The company will pay $450 million on September 3, 2026, receiving an initial delivery of shares equal to 80% of the transaction value based on the closing price on September 2, 2026. Final settlement is scheduled for December 2026 and may occur earlier at Citibank's election. The repurchase is funded by proceeds from the sale of its MatrixCare business and cash on hand, operating under a board-approved authorization for up to 20 million shares established in February 2014. ResMed Inc. operates in the medical technology industry, designing and manufacturing devices for sleep apnea and respiratory care.

On June 30, 2026, ResMed Inc. entered into a definitive agreement to sell its MatrixCare business to Frazier Healthcare Partners for $490 million in cash. The transaction is expected to close in the first quarter of fiscal year 2027. MatrixCare generated approximately $220 million in revenue and $55 million in non-GAAP operating profit for fiscal year 2026. ResMed plans to use net proceeds for general corporate purposes and to return capital to shareholders via an accelerated share repurchase program. Additionally, the company noted that its Noctrix acquisition is expected to add $30 million in revenue but reduce non-GAAP diluted EPS by $0.20 in fiscal year 2027. ResMed operates in the healthcare industry, providing medical devices and software for respiratory and sleep apnea care.